VVOS Vivos Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VVOS

Price (delayed)

$0.68

Market cap

$9.45M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.14

Enterprise value

$19.61M

?
Relative Growth: Rel. Growth: 46
Relative Strength: Rel. Strength: 1
Relative Valuation: Rel. Valuation: 36
Relative Profitability: Rel. Profitability: 11

Vivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea (OSA). Vivos believes that ...

Highlights
The gross profit is up by 41% year-on-year and by 15% since the previous quarter
Vivos Therapeutics's revenue has increased by 34% YoY and by 12% from the previous quarter
The equity has dropped by 132% year-on-year but it has increased by 13% since the previous quarter
The company's quick ratio has shrunk by 66% YoY but it rose by 10% QoQ
The net income has plunged by 122% YoY and by 18% from the previous quarter
VVOS's EPS is down by 24% YoY and by 3.4% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.vivoslife.com
Peers: OFIX

Key stats

What are the main financial stats of VVOS

VVOS stock price

How has the Vivos Therapeutics stock price performed over time
Intraday
5.74%
1 week
1.49%
1 month
-8.66%
1 year
-70.94%
YTD
-66.5%
QTD
-42.37%

Financial performance

How have Vivos Therapeutics's revenue and profit performed over time
Revenue
$19.57M
Gross profit
$12.09M
Operating income
-$22.6M
Net income
-$24.99M
Gross margin
61.8%
Net margin
-127.7%
The net income has plunged by 122% YoY and by 18% from the previous quarter
Vivos Therapeutics's operating income has plunged by 100% YoY and by 14% from the previous quarter
Vivos Therapeutics's net margin has plunged by 66% YoY and by 5% from the previous quarter
The company's operating margin fell by 49% YoY

Price vs fundamentals

How does VVOS's price correlate with its fundamentals

Growth

What is Vivos Therapeutics's growth rate over time

Valuation

What is Vivos Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1
VVOS's EPS is down by 24% YoY and by 3.4% from the previous quarter
The equity has dropped by 132% year-on-year but it has increased by 13% since the previous quarter
VVOS's P/S is 73% below its 5-year quarterly average of 1.8 and 68% below its last 4 quarters average of 1.5
Vivos Therapeutics's revenue has increased by 34% YoY and by 12% from the previous quarter

Efficiency

How efficient is Vivos Therapeutics business performance
The company's return on equity has shrunk by 185% QoQ
VVOS's ROS has plunged by 66% YoY and by 5% from the previous quarter
The return on invested capital has surged by 60% year-on-year but it has declined by 12% since the previous quarter
The company's return on assets fell by 26% YoY and by 2.1% QoQ

Dividends

What is VVOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VVOS.

Financial health

How did Vivos Therapeutics financials performed over time
VVOS's total assets is 4.8% lower than its total liabilities
VVOS's total assets has soared by 122% YoY
The company's quick ratio has shrunk by 66% YoY but it rose by 10% QoQ
The equity has dropped by 132% year-on-year but it has increased by 13% since the previous quarter
Vivos Therapeutics's debt has decreased by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.